In the landscape of modern drug discovery, the traditional animal study has long been viewed as a linear process: dosing, observation, sacrifice, and final report. Once the pathologist signed off on the findings, the glass slides were archived, and the tissue blocks were consigned to long-term storage—effectively closing the book on that specific set of biological data. However, a quiet revolution in digital pathology is transforming these "dead" archives into living, high-value data reservoirs.
By leveraging artificial intelligence (AI), machine learning, and advanced molecular analysis, researchers are now mining these legacy samples to extract insights that were previously invisible. This shift is not merely an academic exercise; it is a critical pillar in the global transition toward reducing, refining, and replacing animal testing in the preclinical pipeline.
The Digital Pivot: From Microscope to Metadata
The rapid adoption of digital pathology was accelerated by the COVID-19 pandemic, which forced pathologists out of the lab and into remote environments. This necessity-driven shift revealed an untapped potential: once a physical slide is converted into a high-resolution digital image, it ceases to be a static visual reference and becomes a searchable, quantifiable data point.
"Before, the pathology endpoint was just a report," explains Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories. "Now, you have the digitized slide, which is pixels. And pixels can be interrogated."
When these digital slides are paired with original study metadata—molecular measurements, dosing protocols, and clinical outcomes—they form a powerful training set for AI models. These models can identify subtle patterns associated with specific biological responses to drugs, enabling researchers to ask new questions of old data without ever needing to touch a laboratory animal.
Chronology of a Paradigm Shift
The transition toward digital, data-driven pathology did not occur overnight. Its trajectory has been defined by a series of technological and regulatory milestones:
- Pre-2020: Digital pathology was largely a niche tool used for collaboration and archival convenience rather than data mining.
- 2020–2022: The global pandemic mandates remote work, forcing widespread adoption of digital slide scanning and cloud-based image analysis.
- December 2022: The U.S. Congress passes the FDA Modernization Act 2.0, signaling a legislative shift that allows non-animal testing methods to support investigational new drug (IND) applications.
- April 2024: Charles River Laboratories launches its "Alternative Methods Advancement Project," a strategic commitment to reducing reliance on traditional animal models.
- April 2025: The FDA publishes a formal roadmap for reducing animal testing in preclinical safety studies, setting a three-to-five-year horizon for making New Approach Methodologies (NAMs) the standard.
- September 2026: Further regulatory updates from the FDA solidify the framework for integrating digital pathology and predictive modeling into safety assessments.
The Power of Virtualization: Reducing the Animal Burden
One of the most promising applications of this digital evolution is the implementation of "virtual control groups." In standard toxicology studies, a significant portion of the animal population is dedicated solely to control groups to establish a baseline for comparison.
"Control animals are always a big fraction of every study," Dr. Zuraw notes. By aggregating historical data from thousands of previous studies, researchers can now create "virtual" baselines. If the data is sufficiently matched, these virtual controls can replace a subset of concurrent animal controls, reducing the overall number of animals required for a study without compromising safety or statistical rigor.
The challenge lies in standardization. For a virtual control to be valid, researchers must prove that the historical conditions are comparable to the current study. Charles River is currently building the infrastructure to generate the deep, matched datasets necessary to make this a reliable, regulatory-grade practice.
Archiving as an Asset: The FFPE Revolution
For decades, the standard for tissue preservation has been the formalin-fixed, paraffin-embedded (FFPE) block. While these blocks were historically treated as static records, they are actually repositories of biological history.
When a drug discovery project hits a hurdle—perhaps an unexpected organ toxicity emerges late in the process—the traditional response has been to launch a new, follow-up animal study. Today, the strategy is changing. Researchers can return to the archived FFPE blocks from the original study and apply modern molecular diagnostics, such as transcriptomics or proteomics, to see how the tissue responded at a molecular level.
The Organisation for Economic Co-operation and Development (OECD) bolstered this approach in 2025, releasing guidance on how to perform omics analysis on archived tissue. This allows scientists to maintain the "study context"—the exact timeline and dosing history of the original animal—while applying cutting-edge analysis to solve new problems. It is the ultimate exercise in research efficiency: getting more from the same animals, from the same blocks, without additional in vivo experiments.
Implications for Future Drug Discovery
The long-term implication of these developments is a fundamental change in the "default" setting of pharmaceutical research. If the FDA’s goal to make animal studies the exception rather than the norm is realized, the role of the pathologist will shift from that of a manual observer to a data scientist.
The Rise of Virtual Staining
Perhaps the most "cutting-edge" development in this field is virtual staining. By scanning unstained tissue, software can generate the appearance of traditional chemical stains (like H&E). This not only reduces the cost and environmental impact of laboratory chemicals but also allows for multiple "stains" to be applied to the same digital slide, revealing different tissue structures without the need for additional physical sections.
The Snowball Effect
For these technologies to move from the research lab to the regulatory suite, the industry requires "early adopters." Dr. Zuraw emphasizes that the field is currently in a phase of establishing precedent. As more companies demonstrate that virtual controls and digital-molecular analysis are as robust—or more robust—than traditional methods, regulators will have the evidence needed to finalize the transition to NAMs as the standard.
"I hope it becomes a snowball effect," says Dr. Zuraw. "We are opening up data sources that aren’t new, but that we simply didn’t have a way to access before."
A New Era of Responsibility
The convergence of digital pathology and regulatory reform represents a significant step forward in the ethical development of medicine. By treating every archived slide as a valuable asset, the pharmaceutical industry is moving toward a more circular research model.
The transition is not without its hurdles; it requires substantial investment in digital infrastructure, rigorous validation of AI models, and a cultural shift among scientists who have relied on traditional methods for a century. Yet, the path is clear. As the "snowball" of digital adoption grows, the reliance on the traditional animal-heavy model will inevitably wane. The future of drug discovery lies not just in the next experiment, but in the intelligent, data-driven re-examination of the vast archives we have already created. Through the lens of digital pathology, the past is finally becoming a bridge to a more humane and efficient future.
About the Author
